References
- Earnshaw SR, McDade CL, Black LK, Bell CF, Kattan MW. Cost effectiveness of 5-α reductase inhibitors for the prevention of prostate cancer in multiple patient populations. Pharmacoeconomics28(6), 489–505 (2010).
- Stephenson AJ, Scardino PT, Eastham JA et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Clin. Oncol.23(28), 7005–7012 (2005).
- Nam RK, Toi A, Klotz LH et al. Assessing individual risk for prostate cancer. J. Clin. Oncol.25(24), 3582–3588 (2007).
- Andriole GL, Bostwick DG, Brawley OW et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med.362(13), 1192–1202 (2010).
- Lepor H, Williford WO, Barry MJ et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N. Engl. J. Med.335(8), 533–539 (1996).
- Kirby RS, Roehrborn C, Boyle P et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology61(1), 119–126 (2003).
- McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med.349(25), 2387–2398 (2003).
- Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med.349(3), 215–224 (2003).
- Kramer BS, Hagerty KL, Justman S et al. Use of 5-α-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J. Clin. Oncol.27(9), 1502–1516 (2009).
- Redman MW, Tangen CM, Goodman PJ et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev. Res. (Phila. PA)1(3), 174–181 (2008).
- Pinsky P, Parnes H, Ford L. Estimating rates of true high-grade disease in the Prostate Cancer Prevention Trial. Cancer Prev. Res. (Phila. PA)1(3), 182–186 (2008).
- Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA293(17), 2095–2101 (2005).
- Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD. Lifetime implications and cost–effectiveness of using finasteride to prevent prostate cancer. Am. J. Med.118(8), 850–857 (2005).
- Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Cost–effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer112(5), 1058–1065 (2008).
- Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. The cost of prostate cancer chemoprevention: a decision analysis model. Cancer Epidemiol. Biomarkers Prev.15(8), 1485–1489 (2006).
- Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med.358(12), 1250–1261 (2008).